DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Ibritumomab tiuxetan
Ibritumomab tiuxetan
Neuro-Ophthalmic Side Effects of Molecularly Targeted Cancer Drugs
Whither Radioimmunotherapy: to Be Or Not to Be? Damian J
Antibody-Drug Conjugates (Adcs) – Biotherapeutic Bullets
Imatinib (Gleevec™)
Hodgkin's Lymphoma Unresponsive to Rituximab Or a Rituximab
Ibritumomab Tiuxetan (Zevalin)
Antibodies for the Treatment of Brain Metastases, a Dream Or a Reality?
Ibritumomab Tiuxetan)
Brentuximab Vedotin (SGN-35)
HPHC Utilization Management Review Criteria 6.16.2020
Highlights in Lymphoma from the 2013 American Society Of
Can You Comment on the Data from the RESORT Trial Recently Presented at ASH 2011?
Tumor Lysis Syndrome Caused by Therapeutic Monoclonal Antibodies Approved by FDA
Zevalin Label
Immunotoxin Screening System: a Rapid and Direct Approach to Obtain Functional Antibodies with Internalization Capacities
Immunoconjugates Advances in the Treatment of Hematologic
Comparing Antibody and Small-Molecule Therapies for Cancer
Development of 64Cu-NOTA-Trastuzumab for HER2 Targeting: Radiopharmaceutical With
Top View
Antibody-Drug Conjugates: Intellectual Property Considerations
Bladder Cancer
Zevalin, INN-Ibritumomab Tiuxetan
Y90 Ibritumomab Tiuxetan and I131 Tositumomab
Zevalin) Regimen: Results from a Zevalin Imaging Registry
Novel Antibodies in the Treatment of Non-Hodgkin's Lymphoma
Radioimmunoconjugates
Pcn43 the Cost of Treating Grade 3/4 Adverse Events
Ibritumomab Tiuxetan (Interim Monograph)
The Evolution of Antibodies Into Versatile Tumor-Targeting Agents
Brentuximab Vedotin and Diffuse Large B-Cell Lymphoma
Biologic & Other Novel Agents
11510B ZEV Patient Brochure R25v4 FIN.Indd
From Current Clinical Success to Future Industrial Breakthrough?
FDA Drug Label
(90Y)-Ibritumomab Tiuxetan in Stem Cell Transplantation for Non-Hodgkin’S Lymphoma
Oncology Therapy for the Generalist
Toxicology Section of the NCI/CIP IND for 89Zr-Panitumumab. This
Monoclonal Antibodies in the Treatment of Non-Hodgkin's
(SITC) Clinical Practice Guideline on Immunotherapy for the Treatment of Lymphoma
Monoclonal Antibodies for the Treatment of Cancer JOSEPH THOMAS PENTO
Biodistribution, Pharmacokinetics and Radioimmunotherapy of 188Re-Cetuximab in NCI-H292 Human Lung Tumor-Bearing Nude Mice
90Y Ibritumomab Tiuxetan
90Y-Ibritumomab Tiuxetan in the Treatment of Relapsed Or Refractory B-Cell Non-Hodgkin’S Lymphoma*
June 30, 2021 Total Approvals 269 This Report Will Be Updated January and July of Every Year
A Radiopharmaceutical with Improved Pharmacokinetics for Human Studies
Monoclonal Antibodies As Therapeutic Agents in Oncology and Antibody Gene Therapy
Current Status and Future Outlook for Biosimilars
Meridian Consult Managed Procedure Code List 2020
Radioimmunotherapy of Lymphoma
Dose-Escalated Radioimmunotherapy As Part of Reduced Intensity Conditioning for Allogeneic Transplantation in Patients with Advanced High-Grade Non-Hodgkin Lymphoma
Comparison of 90Y-Ibritumomab Tiuxetan and 131I-Tositumomab in Clinical Practice
Targeted Treatment of Follicular Lymphoma
Radioimmunotherapy in the Treatment of Non-Hodgkin Lymphoma
Pharmacokinetics of Therapeutic Monoclonal Antibodies Used in Oncology
Zevalin (Ibritumomab Tiuxetan)
Generic (Brand) Name Mechanism of Action Mechanism of Action
Working Minutes of the Ephmra Classification Committee
Radiation Safety Guidelines for Radioimmunotherapy with Yttrium 90 Ibritumomab Tiuxetan
Monoclonal Antibodies in Cancer Therapy: Mechanisms, Successes and Limitations a Coulson, a Levy, M Gossell-Williams
Immunogenicity of Mabs
Radioimmunotherapy
Improved Relative Survival of Patients with B-Cell Non-Hodgkin Lymphoma in Queensland, 1993E2012
Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities
Developments in Therapy with Monoclonal Antibodies and Related Proteins